Library
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy.
1 September 2008. doid: 10.1007/s00432-008-0372-8
Broeyer FJ, Osanto S, Ritsema van Eck HJ, van Steijn AQ, Ballieux BE, Schoemaker RC, Cohen AF, Burggraaf J
View publicationThe clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
